#	Pagina
attuale pagina	/open-h2020/projects/194101/index.html

Opendata, web and dolomites

TREGeneration SIGNED

Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatory T lymphocytes

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

TREGeneration project word cloud

Explore the words cloud of the TREGeneration project. It provides you a very rough idea of what is the project "TREGeneration" about.

collaborative hematopoietic receptor expansion concerted rate agent effectiveness treatment underlying simultaneously host cells successful care organ vivo validity life subsequently comprising tracking sole il ing tissue addressable dominator cell markers survival encompasses parallel treg clinical preparation health trials vitro co mechanisms secondly strategies opportunity induce ultimately sufficient stem therapeutic otherwise agents area patient ex immune regeneration center damage centers therapy rapamycin donor quality cellular ghvd clonotype our expertise administration isolated monitoring gvhd graft prevention understand versus pursued outcome regenerative dosages infusion firstly regulatory hsct disease feasibility transplantation immunotherapy

Project "TREGeneration" data sheet

The following table provides information about the project.

Coordinator	INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES Organization address address: AVENIDA PROF EGAS MONIZ city: LISBOA postcode: 1649 028 website: www.imm.ul.pt contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Portugal [PT]
Project website	http://www.tregeneration.eu
Total cost	5˙899˙250 €
EC max contribution	5˙899˙250 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2014-single-stage
Funding Scheme	RIA
Starting year	2015
Duration (year-month-day)	from 2015-01-01 to 2019-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES Organization address address: AVENIDA PROF EGAS MONIZ city: LISBOA postcode: 1649 028 website: www.imm.ul.pt contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (LISBOA)	coordinator	1˙792˙894.00
2	KLINIKUM DER UNIVERSITAET REGENSBURG KLINIKUM DER UNIVERSITAET REGENSBURG Organization address address: FRANS JOSEF STRAUSS ALLEE 11 city: REGENSBURG postcode: 93053 website: www-cgi.uni-regensburg.de/Klinik/Klinikum/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (REGENSBURG)	participant	1˙348˙823.00
3	MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV Organization address address: HOFGARTENSTRASSE 8 city: MUENCHEN postcode: 80539 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	741˙335.00
4	AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO S. ORSOLA MALPIGHI AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO S. ORSOLA MALPIGHI Organization address address: VIA ALBERTONI 15 city: BOLOGNA postcode: 40138 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (BOLOGNA)	participant	617˙080.00
5	UNIVERSITE DE LIEGE UNIVERSITE DE LIEGE Organization address address: PLACE DU 20 AOUT 7 city: LIEGE postcode: 4000 website: www.ulg.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (LIEGE)	participant	496˙200.00
6	SERVICIO ANDALUZ DE SALUD SERVICIO ANDALUZ DE SALUD Organization address address: AVENIDA DE LA CONSTITUCION 18 city: SEVILLA postcode: 41071 website: http://www.sas.junta-andalucia.es/principal/default.asp contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (SEVILLA)	participant	290˙420.00
7	ALACRIS THERANOSTICS GMBH ALACRIS THERANOSTICS GMBH Organization address address: MAX PLANCK STRASSE 3 city: BERLIN postcode: 12489 website: www.alacris.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	277˙500.00
8	THE UNIVERSITY OF LIVERPOOL THE UNIVERSITY OF LIVERPOOL Organization address address: BROWNLOW HILL 765 FOUNDATION BUILDING city: LIVERPOOL postcode: L69 7ZX website: www.liverpool.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LIVERPOOL)	participant	246˙077.00
9	GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG Organization address address: OSKAR VON MILLER RING 29 city: MUENCHEN postcode: 80333 website: www.gabo-mi.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	88˙919.00

Map

Project objective

Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT). We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not otherwise be addressable by each clinical center on its own. Firstly, by using different Treg preparation strategies, we will be able to determine whether ex vivo isolated Treg are sufficient or whether in vitro expansion and subsequently higher dosages are required. Secondly, we will investigate if sole Treg infusion is effective or if rather co-administration of therapeutic agents that are likely to induce Treg survival and expansion in vivo (rapamycin; IL-2) is required for a successful response to Treg therapy. The studies on GVHD treatment outcome will be pursued together with a detailed analysis of immune monitoring, comprising T cell receptor clonotype tracking and tissue regeneration markers, in order to further understand the mechanisms underlying the therapeutic and regenerative potential of Treg cells. Our consortium has developed a concerted approach to the topic of Treg therapy in GVHD. This is a unique opportunity to determine the validity of this cellular immunotherapy approach in GVHD prevention and treatment, with potential for a significant impact on patient quality of life, survival rate and ultimately on the quality of health care provided.

Deliverables

List of deliverables.
Twitter, Facebook, LinkedIn, Account Setup	Websites, patent fillings, videos etc.	2019-05-08 12:01:41
Launch of website	Websites, patent fillings, videos etc.	2019-05-08 12:01:37
Individualized press release for every partner	Websites, patent fillings, videos etc.	2019-05-08 12:01:32
Development of the project logo	Websites, patent fillings, videos etc.	2019-05-08 12:01:20

Take a look to the deliverables list in detail: detailed list of TREGeneration deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREGENERATION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREGENERATION" are provided by the European Opendata Portal: CORDIS opendata.